Literature DB >> 18991571

Luteolin, a flavonoid with potential for cancer prevention and therapy.

Yong Lin1, Ranxin Shi, Xia Wang, Han-Ming Shen.   

Abstract

Luteolin, 3',4',5,7-tetrahydroxyflavone, is a common flavonoid that exists in many types of plants including fruits, vegetables, and medicinal herbs. Plants rich in luteolin have been used in Chinese traditional medicine for treating various diseases such as hypertension, inflammatory disorders, and cancer. Having multiple biological effects such as anti-inflammation, anti-allergy and anticancer, luteolin functions as either an antioxidant or a pro-oxidant biochemically. The biological effects of luteolin could be functionally related to each other. For instance, the anti-inflammatory activity may be linked to its anticancer property. Luteolin's anticancer property is associated with the induction of apoptosis, and inhibition of cell proliferation, metastasis and angiogenesis. Furthermore, luteolin sensitizes cancer cells to therapeutic-induced cytotoxicity through suppressing cell survival pathways such as phosphatidylinositol 3'-kinase (PI3K)/Akt, nuclear factor kappa B (NF-kappaB), and X-linked inhibitor of apoptosis protein (XIAP), and stimulating apoptosis pathways including those that induce the tumor suppressor p53. These observations suggest that luteolin could be an anticancer agent for various cancers. Furthermore, recent epidemiological studies have attributed a cancer prevention property to luteolin. In this review, we summarize the progress of recent research on luteolin, with a particular focus on its anticancer role and molecular mechanisms underlying this property of luteolin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991571      PMCID: PMC2615542          DOI: 10.2174/156800908786241050

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  156 in total

Review 1.  Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons.

Authors:  K P Miller; K S Ramos
Journal:  Drug Metab Rev       Date:  2001-02       Impact factor: 4.518

2.  Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1.

Authors:  F Casagrande; J M Darbon
Journal:  Biochem Pharmacol       Date:  2001-05-15       Impact factor: 5.858

3.  Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants.

Authors:  K H Miean; S Mohamed
Journal:  J Agric Food Chem       Date:  2001-06       Impact factor: 5.279

Review 4.  Advances in flavonoid research since 1992.

Authors:  J B Harborne; C A Williams
Journal:  Phytochemistry       Date:  2000-11       Impact factor: 4.072

5.  Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids.

Authors:  A M Joussen; K Rohrschneider; J Reichling; B Kirchhof; F E Kruse
Journal:  Exp Eye Res       Date:  2000-11       Impact factor: 3.467

6.  Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization.

Authors:  Ranxin Shi; Qing Huang; Xinqiang Zhu; Yeong-Bing Ong; Bin Zhao; Jia Lu; Choon-Nam Ong; Han-Ming Shen
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

7.  Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages.

Authors:  A Xagorari; A Papapetropoulos; A Mauromatis; M Economou; T Fotsis; C Roussos
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

8.  A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells.

Authors:  Wei Ju; Xia Wang; Honglian Shi; Wenshu Chen; Steven A Belinsky; Yong Lin
Journal:  Mol Pharmacol       Date:  2007-02-12       Impact factor: 4.436

9.  Flavonoids suppress androgen-independent human prostate tumor proliferation.

Authors:  L M Knowles; D A Zigrossi; R A Tauber; C Hightower; J A Milner
Journal:  Nutr Cancer       Date:  2000       Impact factor: 2.900

10.  Caspase activation and extracellular signal-regulated kinase/Akt inhibition were involved in luteolin-induced apoptosis in Lewis lung carcinoma cells.

Authors:  Jin-Hyung Kim; Eun-Ok Lee; Hyo-Jung Lee; Jin-Sook Ku; Min-Ho Lee; Deok-Chun Yang; Sung-Hoon Kim
Journal:  Ann N Y Acad Sci       Date:  2007-01       Impact factor: 5.691

View more
  210 in total

1.  [Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt].

Authors:  Yun Wang; Yuyuan Zhang; Xue Chen; Yun Hong; Zhengdong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Pikuni-Blackfeet traditional medicine: Neuroprotective activities of medicinal plants used to treat Parkinson's disease-related symptoms.

Authors:  Aurélie de Rus Jacquet; Mitali Arun Tambe; Sin Ying Ma; George P McCabe; Jay Hansford C Vest; Jean-Christophe Rochet
Journal:  J Ethnopharmacol       Date:  2017-01-11       Impact factor: 4.360

3.  Anticancer cardamonin analogs suppress the activation of NF-kappaB pathway in lung cancer cells.

Authors:  Weiyan He; Yu Jiang; Xuebing Zhang; Yue Zhang; Honglei Ji; Nan Zhang
Journal:  Mol Cell Biochem       Date:  2014-01-04       Impact factor: 3.396

Review 4.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

5.  Effect of luteolin on the methylation status of the OPCML gene and cell growth in breast cancer cells.

Authors:  Xinmin Dong; Jian Zhang; Fan Yang; Jing Wu; Rui Cai; Tian Wang; Jiren Zhang
Journal:  Exp Ther Med       Date:  2018-07-26       Impact factor: 2.447

6.  N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.

Authors:  Rosalia Crupi; Daniela Impellizzeri; Marika Cordaro; Rosalba Siracusa; Giovanna Casili; Maurizio Evangelista; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-03-19       Impact factor: 5.590

7.  Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.

Authors:  Lan Tang; Ye Li; Wei-Ying Chen; Shan Zeng; Ling-Na Dong; Xiao-Juan Peng; Wen Jiang; Ming Hu; Zhong-Qiu Liu
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

Review 8.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

Review 9.  Mechanisms of testicular torsion and potential protective agents.

Authors:  Ersagun Karaguzel; Mustafa Kadihasanoglu; Omer Kutlu
Journal:  Nat Rev Urol       Date:  2014-06-17       Impact factor: 14.432

Review 10.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.